High baseline CD317 expression on T cells predicts favorable anifrolumab response in systemic lupus erythematosus

Read full text Summarise with VIRAT
Authors: K Kimura, Masahiro Ayano, Shun-ichiro Ota, Kazuo Kushimoto, Yasushi Inoue, Atsushi Tanaka, Keisuke Imabayashi, Sho Fujimoto, Naoya Nishimura, Ayako Takaki-Kuwahara, Yasutaka Kimoto, Hiroki Mitoma
+4 more Nobuyuki Ono, Koichi Akashi, Takahiko Horiuchi, Hiroaki Niiro
Cited by: 0
References: 44

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background Anifrolumab (ANI), a monoclonal antibody blocking the type I interferon (IFN) receptor, is approved for systemic lupus erythematosus (SLE); yet real-world responses vary. We aimed to identify biomarkers predicting clinical response to ANI in SLE. Methods We prospectively enrolled patients with SLE who initiated ANI and evaluated immune cell subsets and type I IFN-associated markers by flow cytometry with respect to clinical response to ANI. Clinical response at 6 months was classified into responders and non-responders based on two criteria: achievement of a British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response and successful glucocorticoid tapering. Results Of the 31 patients analyzed, 15 were responders and 16 were non-responders. Among the ten biomarkers that showed significant changes in responders, four - CD317 expression on T cells, CD317 expression on B cells, CD169 expression on monocytes, and T-peripheral-helper–cell frequency - were already higher at baseline in responders than in non-responders. Baseline CD317 expression on T cells showed the highest discriminative power in predicting 6-month response, separating responders from non-responders with an AUC of 0.89, surpassing the four-gene IFN gene signature (IFNGS) measured by quantitative PCR (qPCR) (DeLong’s test, P = 0.044). Conclusions This study demonstrates that higher baseline CD317 expression on T cells is associated with a favorable clinical response to ANI and predicts this response more accurately than the previously proposed IFNGS in patients with SLE. These findings identify CD317 as a promising and practical candidate biomarker to guide personalized treatment strategies in SLE, contingent upon further validation.

Fields of Study & Subjects

Systemic Lupus Erythematosus Research Systemic Sclerosis and Related Diseases Rheumatoid Arthritis Research and Therapies

Publication details

Journal / source
Frontiers in Immunology
Volume
17
Pages
1756139–1756139
Publication date
26 March 2026
Language
EN